DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder Sep 21, 2021
MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research Jul 27, 2021
MINDCURE Announces Filing of U.S. Provisional Patent Applications for Company’s First Fully Synthetic Routes to… Jul 13, 2021
MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research Jun 3, 2021
MindCure’s Kelsey Ramsden on Psychedelic Rollout: It’s Not Just Regulation; It’s Research Apr 26, 2021
Psychedelics are Now Decriminalized in D.C., Advocates Push for Further Legislative Changes Mar 15, 2021
